{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T04:25:21Z","timestamp":1786940721841,"version":"build-2736575974"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.cca.2022.10.017","type":"journal-article","created":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T11:38:54Z","timestamp":1667648334000},"page":"87-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Instability of uracil in whole blood might affect cancer treatment with fluoropyrimidines"],"prefix":"10.1016","volume":"538","author":[{"given":"Lea","family":"Tybirk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Hoffmann-L\u00fccke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Greibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.cca.2022.10.017_b0005","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1200\/JCO.1995.13.6.1303","article-title":"Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study","volume":"13","author":"Leichman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cca.2022.10.017_b0010","unstructured":"Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA). Assessment report: Fluorouracil and fluorouracil related substances (capecitabine, tegafur and flucytosine) containing medicinal products, 2020. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/fluorouracil-fluorouracil-related-substances-article-31-referral-assessment-report_en.pdf. Accessed July 14, 2022."},{"key":"10.1016\/j.cca.2022.10.017_b0015","unstructured":"INCa and HAS. Screening for dihydropyrimidine dehydrogenase deficiency to decrease the risk of severe toxicities related to fluoropyrimidines (5-fluorouracil or capecitabine), 2018. https:\/\/www.has-sante.fr\/jcms\/c_2891090\/en\/screening-for-dihydropyrimidine-dehydrogenase-deficiency-to-decrease-the-risk-of-severe-toxicities-related-to-fluoropyrimidines-5-fluorouracil-or-capecitabine-inahta-brief. Accessed August 11, 2022."},{"key":"10.1016\/j.cca.2022.10.017_b0020","doi-asserted-by":"crossref","unstructured":"M.C. Etienne-Grimaldi, J.C. Boyer, C. Beroud, L. Mbatchi, A. van Kuilenburg, C. Bobin-Dubigeon, F. Thomas, E. Chatelut, J.L. Merlin, F. Pinguet, C. Ferrand, J. Meijer, A. Evrard, L. Llorca, G. Romieu, P. Follana, T. Bachelot, L. Chaigneau, X. Pivot, V. Dieras, R. Largillier, M. Mousseau, A. Goncalves, H. Roch\u00e9, J. Bonneterre, V. Servent, N. Dohollou, Y. Ch\u00e2teau, E. Chamorey, J.P. Desvignes, D. Salgado, J.M. Ferrero, G. Milano, New advances in DPYD genotype and risk of severe toxicity under capecitabine, PLoS One 12(5) (2017) e0175998.","DOI":"10.1371\/journal.pone.0175998"},{"issue":"1","key":"10.1016\/j.cca.2022.10.017_b0025","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/cpt.2608","article-title":"Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study","volume":"112","author":"de With","year":"2022","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.cca.2022.10.017_b0030","unstructured":"European Medicines Agency (EMA). EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/fluorouracil-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing_en.pdf. Accessed July 14, 2022."},{"issue":"2","key":"10.1016\/j.cca.2022.10.017_b0035","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1080\/17843286.2020.1870855","article-title":"Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur)","volume":"77","author":"Casneuf","year":"2022","journal-title":"Acta Clin Belg"},{"issue":"5","key":"10.1016\/j.cca.2022.10.017_b0040","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1515\/cclm-2021-0921","article-title":"Pre-analytical considerations for the analysis of uracil and 5,6-dihydrouracil in heparin plasma","volume":"60","author":"Capiau","year":"2022","journal-title":"Clin Chem Lab Med"},{"issue":"10","key":"10.1016\/j.cca.2022.10.017_b0045","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/chromsci\/bms085","article-title":"Validation of an ultra-high performance liquid chromatography tandem mass spectrometric method for quantifying uracil and 5,6-dihydrouracil in human plasma","volume":"50","author":"Coudore","year":"2012","journal-title":"J Chromatogr Sci"},{"key":"10.1016\/j.cca.2022.10.017_b0050","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jpba.2016.04.039","article-title":"Development and validation of a rapid and sensitive UPLC-MS\/MS method for determination of uracil and dihydrouracil in human plasma","volume":"126","author":"Jacobs","year":"2016","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"10.1016\/j.cca.2022.10.017_b0055","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jchromb.2005.05.044","article-title":"An accurate dihydrouracil\/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice","volume":"823","author":"Remaud","year":"2005","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.cca.2022.10.017_b0060","author":"Qvortrup","year":"2021","journal-title":"DSKB"},{"issue":"1","key":"10.1016\/j.cca.2022.10.017_b0065","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1515\/cclm-2020-0061","article-title":"The CRESS checklist for reporting stability studies: on behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase (WG-PRE)","volume":"59","author":"Cornes","year":"2020","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"10.1016\/j.cca.2022.10.017_b0070","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1515\/cclm-2015-0067","article-title":"Defining analytical performance specifications: Consensus Statement from the 1st Strategic Conference of the European Federation of Clinical Chemistry and Laboratory Medicine","volume":"53","author":"Sandberg","year":"2015","journal-title":"Clin Chem Lab Med"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898122013511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898122013511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:08:06Z","timestamp":1757862486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898122013511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":14,"alternative-id":["S0009898122013511"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2022.10.017","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Instability of uracil in whole blood might affect cancer treatment with fluoropyrimidines","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2022.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}